BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Active Biotech AB (BTPC) Year-End Report January - December 2012


2/14/2013 9:24:09 AM

LUND, SWEDEN--(Marketwire - February 14, 2013) -


Events for the full year 2012

Laquinimod

* Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)

* Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva

* Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study) in the US

* Positive Crohn's Phase II data presented at the UEGW conference

* Teva expands the clinical development program to encompass new indications


TASQ

* EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase III study

* overall survival data from Phase II study presented

* biomarker data presented at the ESMO conference

* Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate cancer and a second study into additional cancer forms

* Phase III study fully enrolled (1,245 patients); milestone payment of EUR 10 M from Ipsen


ANYARA

* Phase II/III study in renal cell cancer concluded

* Results presented during Q1, 2013:

- study did not achieve primary clinical endpoint

- doubling of progression free survival and OS in 25 % of patients

- planning of the continued clinical development ongoing


57-57

* clinical trial of systemic sclerosis/scleroderma concluded


ISI

* focus on patent submissions H1 2013

* project proceeds as planned


                                        Oct - Dec           Jan - Dec

 (MSEK)                              2012      2011      2012     2011
---------------------------------------------------------------------------
  *      Net sales                   91.5      3.3      227.9     234.6

  *      Operating profit/loss        5.5     -94.7     -163.2   -100.9

  *      Net profit/loss              0.1     -93.2     -175.0    -94.5

  *      Profit/loss per share (SEK)  0.00    -1.35     -2.54     -1.38

This report is also available at www.activebiotech.com

Active Biotech AB Year-end report Jan-Dec 2012: http://hugin.info/1002/R/1678129/547591.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1678129]


For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95

Hans Kolam
CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax +46 (0)46 19 11 00



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES